# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
https://www.genprex.com/downloads/2024-genprex-stockholder-letter.pdf
HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.
HC Wainwright & Co. analyst Yi Chen reiterates Genprex (NASDAQ:GNPX) with a Buy and maintains $10 price target.
Genprex, Inc. ("Genprex" or the "Company") (NASDAQ:GNPX), a clinical-stage gene therapy company focused on deve...
Compelling Data Validates the Potential of Reqorsa® Immunogene Therapy and the Oncoprex® Delivery System as Innovative Cancer T...